NCT05801913 2026-03-05
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 1 Recruiting
Clinical Trials
8 trialsNCT06191887 2026-02-13
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Mayo Clinic
Phase 1 Recruiting
NCT07097363 2026-01-15
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
University of Washington
Phase 2 Recruiting
NCT05821088 2025-11-20
Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT03017820 2025-10-08
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic
Phase 1 Recruiting
NCT05507541 2025-08-29
TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Mayo Clinic
Phase 2 Active not recruiting
NCT04892277 2025-07-01
CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
Mayo Clinic
Phase 1 Recruiting
NCT05936229 2024-07-12
Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy
Fred Hutchinson Cancer Center
Phase 1/2 Withdrawn